Core Insights - Creative Medical Technology Holdings, Inc. announced positive mid-term follow-up data from its StemSpine® pilot study, which utilizes AlloStem™ cells for treating chronic lower back pain [1][2] Study Results - The pilot study showed a significant reduction in opioid dependency, with over 90% of patients reporting no opioid use for pain management three years post-procedure [2] - Pain scores decreased by 80%, and there was a greater than 60% improvement in Oswestry Disability Index scores [2] - Only one patient required reintervention at the three-year follow-up, and no serious adverse events were reported, indicating a favorable safety profile for the StemSpine® procedure [2] Technology Overview - StemSpine® is a patented, non-surgical, ultrasound-guided procedure that employs AlloStem™, an allogenic cell therapy developed by the company [3] - The patent for StemSpine® includes the use of both autologous and allogenic cells, enhancing its clinical applicability [3] Company Vision - The results highlight the safety and clinical efficacy of AlloStem™ in the StemSpine® procedure, promoting repair and improved vascularization in affected areas [4] - The company aims to provide innovative, non-surgical solutions for individuals suffering from chronic lower back pain [4] - The positive findings from the pilot study are expected to drive strong enrollment in the ongoing FDA-cleared Phase 1/2 ADAPT clinical trial for CELZ-201-DDT [4]

Core Insights - Creative Medical Technology Holdings, Inc. announced promising one-year follow-up data from the AlloStem (CELZ-201) pilot study for late-stage Type 2 Diabetes, demonstrating significant efficacy and safety [1][2][3] Study Results - CELZ-201 achieved an 80% overall efficacy rate in reducing insulin dependency and stabilizing hemoglobin A1c levels, with no serious adverse effects reported [2][3] - The study involved 20 patients, with 10 receiving CELZ-201 and 10 undergoing optimized medical therapy, validating the safety and efficacy of CELZ-201 [3] Future Development Plans - The company plans to advance the development of AlloStem (CELZ-201) for late-stage Type 2 Diabetes and explore other potential applications to expand its pipeline [4] - The positive data represents a significant milestone in the company's mission to revolutionize diabetes treatment [5] Company Overview - Creative Medical Technology Holdings, Inc. is a clinical-stage biotechnology company focused on developing regenerative cell therapies targeting various conditions, including endocrinology and immunotherapy [7]

Core Insights - Creative Medical Technology Holdings, Inc. has announced an expanded agreement with Greenstone Biosciences to utilize Artificial Intelligence in the development of its human induced pluripotent stem cell platform for diabetes treatment [1][2]. Group 1: Strategic Collaboration - The collaboration aims to enhance Creative Medical's hypoimmune iPSC technology, particularly its iPSC-derived pancreatic islet cells, which are currently in clinical trials [2]. - The integration of AI-driven drug discovery is expected to identify small molecules that improve insulin secretion, thereby refining the therapeutic potential of the iPSC-derived pancreatic islet cells [2][3]. - The program will also focus on multi-gene editing to create next-generation hypoimmune iPSC lines with improved stealth, survival, and differentiation capabilities [2][6]. Group 2: Addressing Clinical Challenges - A major challenge in stem cell therapies is the need for immunosuppression, which can cause severe side effects. Creative Medical aims to overcome this by refining hypoimmune iPSC lines through AI-guided development [3][6]. - The advancements in multi-gene edited hypoimmune iPSCs could eliminate the need for immunosuppression, significantly enhancing patient outcomes in regenerative therapies [6]. Group 3: Leadership and Vision - The President and CEO of Creative Medical emphasized that the partnership with Greenstone represents a significant milestone in the company's mission to develop transformative therapies [4]. - The incorporation of AI methodologies is projected to reduce R&D time by approximately 50% and generate millions of dollars in cost savings, positioning the company as a leader in personalized medicine [5]. Group 4: Company Overview - Creative Medical Technology Holdings, Inc. is focused on developing innovative regenerative therapies using stem cell and immune modulation technologies, targeting conditions such as diabetes, autoimmune disorders, and neurological diseases [8].

Core Insights - Creative Medical Technology Holdings, Inc. announced promising initial data from its Phase 1/2 clinical trial of CELZ-201-DDT, a stem cell-based therapy for chronic back pain due to degenerative disc disease [1][2] - The first cohort of 10 participants completed the study without any dose-limiting toxicities or serious adverse events, indicating a strong safety profile [2][8] - Preliminary blinded data suggests potential therapeutic benefits in alleviating back pain and restoring functionality, leading to the recommendation from the Data Safety Monitoring Board (DSMB) to proceed to the next cohort [2][8] Company Commitment - The company emphasizes its commitment to addressing chronic back pain, a condition with limited effective treatment options, and believes CELZ-201-DDT could transform the standard of care for patients [4][5] - CELZ-201-DDT aims to leverage stem cell technology to address the root causes of pain and degenerative conditions, providing a novel, non-opioid therapeutic option [4][5] Study Design and Future Plans - The Phase 1/2 study is designed to evaluate the safety, efficacy, and tolerability of CELZ-201-DDT, with plans to enroll 30 individuals suffering from chronic lower back pain [6][8] - Enrollment for the second cohort is expected in the first quarter of 2025, with comprehensive data from subsequent cohorts guiding future clinical and regulatory plans [8]

Core Insights - Creative Medical Technology Holdings, Inc. has successfully completed an independent interim safety review for its ADAPT clinical trial evaluating CELZ-201, a novel therapeutic product for chronic lower back pain [1][2][3] - The Data Safety Monitoring Board (DSMB) concluded that the trial may proceed, highlighting the safety profile of CELZ-201 and supporting its advancement [2][3] - The ADAPT trial is a double-blind, randomized, placebo-controlled, dose-escalation study designed to assess the safety, tolerability, and efficacy of CELZ-201 [3][4] Company Overview - Creative Medical Technology Holdings, Inc. is a clinical-stage biotechnology company focused on regenerative medicine therapies derived from adult stem cells [5] - The company aims to develop targeted cellular therapies to address unmet medical needs, particularly in degenerative diseases [4][5] - CELZ-201 represents the company's commitment to delivering transformative treatments for patients suffering from chronic conditions [4][5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 000-53500 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (Exact name of Registrant as specified in its charter) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 000-53500 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (Exact name of Registrant as specified in its charter) | --- ...

Conor Rodriguez, Analyst crodriguez@equityny.com PHOENIX, July 24, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial-stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that it has initiated its planned program to diagnose and treat patients exposed to biological and chemical weapons by combining Artificial Intelligence (AI) ...

About Artificial Intelligence in Medicine Conor Rodriguez, Analyst crodriguez@equityny.com PHOENIX, July 24, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial-stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that it has initiated its planned program to diagnose and treat patients exposed to biological and chemical weapons ...

During 2023, the Company received IND clearance from the FDA on a Phase I/II clinical trial of AlloStemSpine™ to treat Chronic Lower Back Pain (CELZ-201 ADAPT) using AlloStem™ (CELZ-201- DDT). This is a minimally invasive outpatient procedure with direct injection of the cell-based therapy into the patient using targeted ultrasound guidance. During the first six months of 2024 the Company received IRB approval, selected and initiated the trial site, and initiated patient recruitment. The Company expects to ...